by Damon Race | Jul 23, 2024 | Press
July 23, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that Sylvia Fong, Ph.D. has joined the Company’s Scientific Advisory Board as the...
by Damon Race | Mar 13, 2024 | Press
March 13 2024 ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based...
by Damon Race | Jan 30, 2024 | Press
January 30, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the BIO CEO & Investor Conference, which will be held in New York, NY from...
by Damon Race | Nov 30, 2023 | Press
November 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the Biotech Showcase and BIO Partnering meetings during the J.P. Morgan...
by Damon Race | Oct 10, 2023 | Press
October 10, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Europe Fall 2023, which will be held from November 14-15, 2023. GeneVentiv...
by Damon Race | Oct 2, 2023 | Press
October 2, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Investor Forum, which will be held in San Francisco, CA from October 17-18,...
Recent Comments